SW-682 is an investigational novel, oral, potent, and selective pan-TEAD inhibitor and patients are being enrolled in a Phase 1a trial in Hippo-mutant solid tumors. In July, SpringWorks appointed ...

接下来，研究人员借助多体素模式分析（MVPA: Multivoxel Pattern ...

Jacob Gaylord ran for three second-half touchdowns and rallied Gravette past Gentry in a 4A-1 Conference showdown between ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...